全文获取类型
收费全文 | 1238篇 |
免费 | 53篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 13篇 |
妇产科学 | 22篇 |
基础医学 | 24篇 |
口腔科学 | 11篇 |
临床医学 | 163篇 |
内科学 | 436篇 |
皮肤病学 | 4篇 |
神经病学 | 101篇 |
特种医学 | 20篇 |
外科学 | 210篇 |
综合类 | 119篇 |
预防医学 | 23篇 |
眼科学 | 4篇 |
药学 | 125篇 |
中国医学 | 11篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 22篇 |
2022年 | 46篇 |
2021年 | 58篇 |
2020年 | 56篇 |
2019年 | 52篇 |
2018年 | 75篇 |
2017年 | 78篇 |
2016年 | 61篇 |
2015年 | 50篇 |
2014年 | 104篇 |
2013年 | 94篇 |
2012年 | 59篇 |
2011年 | 63篇 |
2010年 | 55篇 |
2009年 | 79篇 |
2008年 | 75篇 |
2007年 | 67篇 |
2006年 | 49篇 |
2005年 | 25篇 |
2004年 | 23篇 |
2003年 | 20篇 |
2002年 | 16篇 |
2001年 | 5篇 |
2000年 | 12篇 |
1999年 | 8篇 |
1998年 | 7篇 |
1997年 | 11篇 |
1996年 | 6篇 |
1995年 | 2篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有1316条查询结果,搜索用时 15 毫秒
41.
Objective
Long-term oral anticoagulation or antiplatelet therapy has been used with increasing frequency in the elderly. These patients are at increased risk of morbidity and mortality from expansion of intracranial hemorrhage. We conducted a single-center retrospective case control study to evaluate risk factors associated with outcomes and to identify the differences in outcome in traumatic brain injury between preinjury anticoagulation use and without anticoagulation.Methods
A retrospective study of patients who underwent craniotomy or craniectomy for acute traumatic cerebral hemorrhage, between January 2005 and December 2014 was performed.Results
A consecutive series of 50 patients were evaluated. The factors significantly differed between the two groups were initial Prothrombin Time-International Normalized Ratio, initial platelet count, initial Glasgow Coma Scale score, and postoperative intracranial bleeding. Mean Glasgow Outcome Scale (GOS) score were similar between the two groups. In the patient with low-energy trauma only, no significant differences in GOS score, postoperative bleeding and many other factors were observed. The contributing factors to postoperative bleeding was preinjury anticoagulation and its adjusted odds ratio was 12 [adjusted odds ratio (OR), 12.242; p=0.0070]. The contributing factors to low GOS scores, which mean unfavorable neurological outcomes, were age (adjusted OR, 1.073; p=0.039) and Rotterdam scale score for CT scans (adjusted OR, 3.123; p=0.0020).Conclusion
Preinjury anticoagulation therapy contributed significantly to the occurrence of postoperative bleeding. However, preinjury anticoagulation therapy in the patients with low-energy trauma did not contribute to the poor clinical outcomes or total hospital stay. Careful attention should be given to older patients and severity of hemorrhage on initial brain CT. 相似文献42.
BACKGROUND: Antibiotics can potentiate warfarin anticoagulation. While preemptive warfarin dose reduction (DR) upon initiation of antibiotics has been advocated by experts, there are no published data regarding the efficacy of this strategy vs. the conventional strategy of not changing warfarin dose and carefully following international normalized ratio (INR) results. METHODS AND RESULTS: We compared the efficacy of preemptive 10-20% DR vs. no change in warfarin dosing in 40 chronically anticoagulated patients initiating trimethoprim-sulfamethoxazole (TMP-SMX) or levofloxacin. Eighteen patients received preemptive warfarin DR and 22 control patients underwent no change in warfarin dosing. There was no difference between the DR and control groups in the mean INR before beginning antibiotic therapy (2.53 +/- 0.12 vs. 2.52 +/- 0.11; P > 0.9). Mean interval between initiation of antibiotic and next INR was 5.1 +/- 0.4 vs. 4.7 +/- 0.5 days for DR vs. control patients, respectively (P > 0.5). For both TMP-SMX and levofloxacin, patients managed with a preemptive warfarin DR strategy did not exhibit a statistically significant change in the INR after initiating antibiotic therapy. In contrast, for each antibiotic, control group patients exhibited a significant increase in mean post-antibiotic INR compared to mean pre-antibiotic INR, though the effect was more pronounced in patients treated with TMP-SMX than with levofloxacin. Of DR group patients who were treated with TMP-SMX, none (0/8) developed a subtherapeutic INR, while 40% (4/10) of levofloxacin-treated patients developed a sub-therapeutic INR. Supra-therapeutic INR results led to transient interruption of warfarin dosing in 2 patients (11%) in the DR group vs. 12 patients (55%) in the control group (P = 0.007). CONCLUSIONS: Prophylactic warfarin DR of 10-20% is effective in maintaining therapeutic anticoagulation in patients initiating TMP-SMX. An expectant strategy consisting of no change in warfarin dosing with short-term INR follow-up appears reasonable in patients treated with levofloxacin. 相似文献
43.
David Vivas Inmaculada Roldán Raquel Ferrandis Francisco Marín Vanessa Roldán Antonio Tello-Montoliu Juan Miguel Ruiz-Nodar Juan José Gómez-Doblas Alfonso Martín Juan Vicente Llau María José Ramos-Gallo Rafael Muñoz Juan Ignacio Arcelus Francisco Leyva Fernando Alberca Raquel Oliva Ana María Gómez Carmen Montero Andrés Íñiguez 《Revista espa?ola de cardiología》2018,71(7):553-564
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice.Full English text available from: www.revespcardiol.org/en 相似文献
44.
《Clinics and research in hepatology and gastroenterology》2020,44(4):438-446
45.
Nontumoral portal vein thrombosis (PVT) is an increasingly recognized complication in patients with cirrhosis. Substantial evidence shows that portal flow stasis, complex thrombophilic disorders, and exogenous factors leading to endothelial dysfunction have emerged as key factors in the pathogenesis of PVT. The contribution of PVT to hepatic decompensation and mortality in cirrhosis is debatable; however, the presence of an advanced PVT increases operative complexity and decreases survival after transplantation. The therapeutic decision for PVT is often determined by the duration and extent of thrombosis, the presence of symptoms, and liver transplant eligibility. Evidence from several cohorts has demonstrated that anticoagulation treatment with vitamin K antagonist or low molecular weight heparin can achieve recanalization of the portal vein, which is associated with a reduction in portal hypertension-related events and improved survival in cirrhotic patients with PVT. Consequently, interest in direct oral anticoagulants for PVT is increasing, but clinical data in cirrhosis are limited. Although the most feared consequence of anticoagulation is bleeding, most studies indicate that anticoagulation therapy for PVT in cirrhosis appears relatively safe. Interestingly, the data showed that transjugular intrahepatic portosystemic shunt represents an effective adjunctive therapy for PVT in cirrhotic patients with symptomatic portal hypertension if anticoagulation is ineffective. Insufficient evidence regarding the optimal timing, modality, and duration of therapy makes nontumoral PVT a challenging consequence of cirrhosis. In this review, we summarize the current literature and provide a potential algorithm for the management of PVT in patients with cirrhosis. 相似文献
46.
作为临床上常见的心律失常类型之一,心房颤动在人群中的患病率逐渐增加,因此不断优化心房颤动的诊断管理十分重要。2020年欧洲心脏病协会联合心胸外科协会发布的心房颤动管理指南是2016年ESC房颤指南的进一步更新,新指南对房颤的定义、诊断、危险因素、临床结局、综合管理、治疗、预防等方面进行了更新。本文重点对指南的更新处进行解读,尤其是整合管理方法(即ABC途径)进行解读,旨在为临床工作者管理房颤病人提供最新思路。 相似文献
47.
Ashish Aggarwal Kanika Puri Suthat Liangpunsakul 《World journal of gastroenterology : WJG》2014,20(19):5737-5745
Patients with liver cirrhosis were traditionally believed to be protected against development of blood clots.Lately,studies have shown that these patients may probably be at an increased risk of venous thrombotic complications.Although the hemostatic changes in the chronic liver disease patients and the factors that may predict bleeding vs thrombotic complications remains an area of active research,it is believed that the coagulation cascade is delicately balanced in these patients because of parallel reduced hepatic synthesis of pro and anticoagulant factors.Thrombotic state in cirrhotic patients is responsible for not only portal or non-portal thrombosis[deep vein thrombosis(DVT)and pulmonary embolism(PE)];it has also been associated with progression of liver fibrosis.The use of anticoagulants in cirrhosis patients is a challenging,and often a scary situation.This review summarizes the current literature on the prevalence of venous thrombosis(DVT and PE),risk factors and safety of prophylactic and therapeutic anticoagulation in patients with chronic liver disease. 相似文献
48.
Nao Kinjo Hirofumi Kawanaka Tomohiko Akahoshi Yoshi-hiro Matsumoto Masahiro Kamori Yoshihiro Nagao Naotaka Hashimoto Hideo Uehara Morimasa Tomikawa Ken Shirabe Yoshihiko Maehara 《World journal of hepatology》2014,(2)
Portal vein thrombosis(PVT) is considered to be a frequent complication of liver cirrhosis. However, unlike PVT in patients without cirrhosis, very few data are available on the natural history and management of PVT in cirrhosis, despite its association with potentially life-threatening conditions, such as gastroesophageal bleeding and acute intestinal ischemia. Moreover, no consensus regarding PVT in cirrhosis exists. Suggested causes of PVT in cirrhosis include reduced portal blood flow velocity, multiple congenital or acquired thrombophilic factors, inherited or acquired conditions, and derangement of liver architecture. However, the understanding of PVT in cirrhosis is incomplete. In addition, information on the management of PVT in cirrhosis is inadequate. The aims of this review are to:(1) assemble data on the physiopathological mechanism, clinical findings, diagnosis and management of PVT in cirrhosis;(2) describe the principal factors most frequently involved in PVT development; and(3) summarize the recent knowledge concerning diagnostic and therapeutic procedures. 相似文献
49.
Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits?
Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion. 相似文献
50.
目的探讨老年重型胰腺炎患者机体内凝血和抗凝系统的变化情况,分析凝血、抗凝指标对疾病发展程度的意义。方法收集2009年10月-2013年10月湖北医药学院附属太和医院收治的重型胰腺炎老年患者44例作为观察组,同期选择健康人群24例作为对照A组,同期选择老年轻型胰腺炎患者24例作为对照B组,对三组入选受试者进行血液样本采集,检测和记录标本凝血酶原时间(PT)、部分活化凝血酶原时间(APTT)、纤维蛋白原(FIB)D-二聚体。结果观察组PT、APTT、FIB和D-二聚体均明显高于对照A组和对照B组(P0.05)。结论老年重型胰腺炎患者机体内的凝血和抗凝系统明显异于常态时,可以直接影响到正常的微循环,同时凝血和抗凝系统指标患者病情发展的程度,有助于评估。 相似文献